Myelodysplastic syndromes;
Hematologic malignancies;
Drug therapy;
Bone marrow transplantation;
STEM-CELL TRANSPLANTATION;
PROGNOSTIC SCORING SYSTEM;
RETROSPECTIVE MULTICENTER ANALYSIS;
CONVENTIONAL CARE REGIMENS;
IDENTICAL SIBLING DONORS;
ACUTE MYELOID-LEUKEMIA;
DECISION-ANALYSIS;
OLDER PATIENTS;
PHASE-III;
THERAPY;
D O I:
10.1016/j.canep.2015.01.006
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose: The heterogeneous nature of myelodysplastic syndromes (MDS) complicates therapeutic decision making, particularly for newly diagnosed disease. Factors impacting the treatment plan in this early period of disease course are poorly defined. This study determines whether therapeutic choices for newly diagnosed MDS are associated with location of treatment (community or academic), prognostic risk category, and patient age. Methods: The adults in Minnesota with myelodysplastic syndromes (AIMMS) database was utilized in this statewide, prospective population-based study conducted by the University of Minnesota (UMN), Mayo Clinic, and Minnesota Department of Health. Adult (age 20+ years) cases of MDS newly diagnosed starting in April 2010 were invited to participate. This analysis includes patients enrolled during the first study year with 1-year follow-up data. Treatment choices (supportive, active, and transplant) were stratified by the international prognostic scoring system (IPSS) and the revised-IPSS (IPSS-R), then separated into groups by location of care and age (<65 or 65+ years). Academic-based care was any contact with the UMN and Mayo Clinic; community-based care was all other clinical sites. Results: Stratification by IPSS and IPSS-R showed supportive care decreased and active care increased with advancing risk categories (p < 0.0001). Comparing treatment setting, community-based care had 77% supportive and 23% active treatment; academic-based care was 36% supportive, 41% active, and 23% transplant (p < 0.0001). By age groups, patients < 65 years with intermediate, high, or very high risk disease by IPSS-R received 97% active care/transplant, compared to only 52% of patients age 65+. Conclusions: Younger patients and those treated at academic centers had a more aggressive treatment approach. Whether these treatment differences convey improved disease control and mortality, and therefore should be extended more frequently to older and community-based patients, is the subject of ongoing prospective study. (C) 2015 Elsevier Ltd. All rights reserved.
机构:
Charles Univ Prague, Gen Univ Hosp, Dept Med 1, Prague, Czech Republic
Charles Univ Prague, Fac Med 1, Prague, Czech RepublicCharles Univ Prague, Inst Med Biochem, Ctr Oncocytogenet, Prague, Czech Republic
Siskova, M.
Jonasova, A.
论文数: 0引用数: 0
h-index: 0
机构:
Charles Univ Prague, Gen Univ Hosp, Dept Med 1, Prague, Czech Republic
Charles Univ Prague, Fac Med 1, Prague, Czech RepublicCharles Univ Prague, Inst Med Biochem, Ctr Oncocytogenet, Prague, Czech Republic
Jonasova, A.
Neuwirtova, R.
论文数: 0引用数: 0
h-index: 0
机构:
Charles Univ Prague, Gen Univ Hosp, Dept Med 1, Prague, Czech Republic
Charles Univ Prague, Fac Med 1, Prague, Czech RepublicCharles Univ Prague, Inst Med Biochem, Ctr Oncocytogenet, Prague, Czech Republic
机构:
Univ Utah, Salt Lake City, UT USA
ARUP Labs, Salt Lake City, UT USAUniv Utah, Salt Lake City, UT USA
George, Tracy I.
Cogle, Christopher R.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Florida, Med, Gainesville, FL USAUniv Utah, Salt Lake City, UT USA
Cogle, Christopher R.
Garcia-Manero, Guillermo
论文数: 0引用数: 0
h-index: 0
机构:
MD Anderson Canc Ctr, Houston, TX USAUniv Utah, Salt Lake City, UT USA
Garcia-Manero, Guillermo
Grinblatt, David L.
论文数: 0引用数: 0
h-index: 0
机构:
NorthShore Univ HealthSyst, Evanston, IL USAUniv Utah, Salt Lake City, UT USA
Grinblatt, David L.
Komrokji, Rami
论文数: 0引用数: 0
h-index: 0
机构:
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USAUniv Utah, Salt Lake City, UT USA
Komrokji, Rami
Savona, Michael R.
论文数: 0引用数: 0
h-index: 0
机构:
Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
Vanderbilt Univ, Med Ctr, Program Canc Biol, Nashville, TN USAUniv Utah, Salt Lake City, UT USA
Savona, Michael R.
Scott, Bart L.
论文数: 0引用数: 0
h-index: 0
机构:
Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USAUniv Utah, Salt Lake City, UT USA
Scott, Bart L.
Sekeres, Mikkael A.
论文数: 0引用数: 0
h-index: 0
机构:
Cleveland Clin, Cleveland, OH 44106 USAUniv Utah, Salt Lake City, UT USA
Sekeres, Mikkael A.
Steensma, David P.
论文数: 0引用数: 0
h-index: 0
机构:
Dana Farber Canc Inst, Boston, MA 02115 USAUniv Utah, Salt Lake City, UT USA
Steensma, David P.
Flick, E. Dawn
论文数: 0引用数: 0
h-index: 0
机构:
Celgene Corp, San Francisco, CA USAUniv Utah, Salt Lake City, UT USA
Flick, E. Dawn
Kiselev, Pavel
论文数: 0引用数: 0
h-index: 0
机构:
Celgene Corp, Summit, NJ USAUniv Utah, Salt Lake City, UT USA
Kiselev, Pavel
Louis, Chrystal U.
论文数: 0引用数: 0
h-index: 0
机构:
Celgene Corp, Summit, NJ USAUniv Utah, Salt Lake City, UT USA
Louis, Chrystal U.
Nifenecker, Melissa
论文数: 0引用数: 0
h-index: 0
机构:
Celgene Corp, Summit, NJ USAUniv Utah, Salt Lake City, UT USA
Nifenecker, Melissa
Swern, Arlene S.
论文数: 0引用数: 0
h-index: 0
机构:
Celgene Corp, Summit, NJ USAUniv Utah, Salt Lake City, UT USA
Swern, Arlene S.
Foucar, Kathryn
论文数: 0引用数: 0
h-index: 0
机构:
Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USAUniv Utah, Salt Lake City, UT USA